Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Dificid, Dificlir
Fidaxomicin is a macrocyclic antibiotic indicated for the treatment of Clostridium difficile-associated diarrhea (CDAD). It acts by inhibiting bacterial RNA polymerase, specifically targeting the sigma subunit, which disrupts bacterial protein synthesis and leads to cell death. Fidaxomicin is narrow-spectrum, primarily affecting C. difficile, with minimal impact on the normal gut flora. It's available as an oral medication.
For the treatment of Clostridium difficile-associated diarrhea (CDAD).
Outcome:
Increased ciclosporin levels
Mechanism:
Inhibition of CYP3A4 enzyme
Outcome:
Decreased fidaxomicin levels
Mechanism:
Induction of CYP3A4 enzyme
Outcome:
Reduced fidaxomicin absorption
Mechanism:
Chelation or altered pH
Most likely new formulation: A sustained-release formulation for improved patient compliance (Year: 2026, 75% confidence).
Based on current usage trends and clinical trial data, there is a 90% likelihood that fidaxomicin will maintain its current FDA approval status for CDAD treatment.
Antibacterial, Macrolide
Macrolide